NCT05109364Active, not recruitingPhase 2
Terazosin and Parkinson's Disease Extension Study
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated to the presence and severity of motor and non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic function tests.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 13 Oct 2021
- Start date
- 23 Sept 2022
- Primary completion date
- 10 Mar 2026
- Lead sponsor
- Cedars-Sinai Medical Center
- Diseases
- Parkinson disease
- NCT number
- NCT05109364
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 15
- From 23 Sept 2022 to the primary completion date, 10 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent dementia defined by a score lower than 22 on The Montreal Cognitive Assessment (MoCA)
- Concurrent severe depression defined by a Beck Depression Inventory-Fast Screen (BDI fast screen) score greater than 13
- Concurrent Use of Beta-adrenergic antagonist
- Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)
- Use of investigational drugs within 30 days before screening
Other illness
- Recent myocardial revascularization (\<12 weeks)
- Hypertension (systolic blood pressure SBP\>150mmHg (millimeters of mercury) or diastolic blood pressure DBP\>100mmHg)
- Diabetes mellitus
- Chronic Obstructive Pulmonary Disease (COPD)
- Recent myocardial infarction (\<48 h)
- Ongoing angina pectoris
- History of priapism (persistent and painful erection)
- Allergy/hypersensitivity to iodine or study medication
Lab values
- Heart failure (LVEF \<45%)
Other
- Secondary Parkinsonism, including tardive
- Comorbidities related to sympathetic nervous system (SNS) hyperactivity
- Chronic Atrial fibrillation
- Untreated Sever Sleep Apnea; Apnea-Hypopnea Index (AHI) \> 30/h.
- Severely reduced kidney function (Glomerular Filtration Rate\<30ml/min)
- Contraindications to the use of terazosin
- Cardiogenic shock or prolonged hypotension
- Breast-feeding
- Neurogenic orthostatic hypotension defined as symptomatic decrease in BP \> 20mmHg systolic or \> 10mmHg diastolic and HR increase \< 20bpm on supine to sitting or standing.
- Blood pressure less than 110 mm Hg systolic at screening or baseline visit
- For female participant, pregnancy, or plans for child-bearing during study period
Who the study is looking for
- Enrolled in the study "The Effect of alpha1- adrenergic receptor antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease" (STUDY #000540)
- Capacity to give informed consent
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cedars-Sinai Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.